HighTower Advisors
HRTX icon

HighTower Advisors’s Heron Therapeutics HRTX Stock Holding History

HighTower Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-500
Closed -$1K – 2466
2019
Q2 		$1K Buy
+500
New +$9.99K ﹤0.01% 2366
2018
Q1 		– Sell
-500
Closed -$2K – 2259
2017
Q4 		$2K Buy
+500
New +$8.15K ﹤0.01% 2236

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

HighTower Advisors's HRTX Position: Q2 2026 in Review

HighTower Advisors increased its Heron Therapeutics (HRTX) stake by 40% in Q2 2026, buying an estimated $5.62K and bringing the position to 24,617 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3786.

HighTower Advisors first reported a position in HRTX in Q2 2015 and has held it in 32 quarters since. The position peaked at $749K in Q2 2018. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • HighTower Advisors held 24,617 shares of Heron Therapeutics worth $10.5K as of Q2 2026.
  • HighTower Advisors bought 7,005 Heron Therapeutics shares in Q2 2026, an estimated $5.62K.
  • Heron Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3786 holding.
  • HighTower Advisors first reported a position in Heron Therapeutics in Q2 2015 and has held it in 32 quarters since.
  • HighTower Advisors's Heron Therapeutics position peaked at $749K in Q2 2018.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.